

Amendments to the Claims

- 1.) (original) A binding molecule which is capable of binding to the human NogoA polypeptide (SEQ ID NO: 5) or human NiG (SEQ ID NO: 7) or human NiG-D20 (SEQ ID NO: 24) or human NogoA_623-640 (SEQ ID NO: 6) with a dissociation constant < 1000nM.
- 2.) (original) A binding molecule which is capable of binding to the human NogoA polypeptide (SEQ ID NO: 5) or human NiG (SEQ ID NO: 7) or human NiG-D20 (SEQ ID NO: 24) or human NogoA_623-640 (SEQ ID NO: 6) with a dissociation constant < 1000nM and comprises at least one antigen binding site, said antigen binding site comprising either
 - in sequence the hypervariable regions CDR1, CDR2, and CDR3, of which each of the hypervariable regions are at least 50% homologous to their equivalent hypervariable regions CDR1-11C7 (SEQ ID NO: 8), CDR2-11C7 (SEQ ID NO: 9) and CDR3-11C7 (SEQ ID NO: 10); or
 - in sequence the hypervariable regions CDR1', CDR2', and CDR3', of which each of the hypervariable regions are at least 50% homologous to their equivalent hypervariable regions CDR1'-11C7 (SEQ ID NO: 11), CDR2'-11C7 (SEQ ID NO: 12) and CDR3'-11C7 (SEQ ID NO: 13).
- 3.) (original) A binding molecule which is capable of binding to the human NogoA polypeptide (SEQ ID NO: 5) or human NiG (SEQ ID NO: 7) or human NiG-D20 (SEQ ID NO: 24) or human NogoA_623-640 (SEQ ID NO: 6) with a dissociation constant < 1000nM and comprises
 - a first antigen binding site comprising in sequence the hypervariable regions CDR1, CDR2, and CDR3, of which each of the hypervariable regions are at least 50% homologous to their equivalent hypervariable regions CDR1-11C7 (SEQ ID NO: 8), CDR2-11C7 (SEQ ID NO: 9) and CDR3-11C7 (SEQ ID NO: 10); and
 - a second antigen binding site comprising in sequence the hypervariable regions CDR1', CDR2', and CDR3', of which each of the hypervariable regions are at least 50% homologous to their equivalent hypervariable regions CDR1'-11C7 (SEQ ID NO: 11), CDR2'-11C7 (SEQ ID NO: 12) and CDR3'-11C7 (SEQ ID NO: 13).
- 4.) (original) A binding molecule which comprises at least one antigen binding site, said antigen binding site comprising either
 - in sequence the hypervariable regions CDR1-11C7 (SEQ ID NO: 8), CDR2-11C7 (SEQ ID NO: 9) and CDR3-11C7 (SEQ ID NO: 10); or
 - in sequence the hypervariable regions CDR1'-11C7 (SEQ ID NO: 11), CDR2'-11C7 (SEQ ID NO: 12) and CDR3'-11C7 (SEQ ID NO: 13); or

- direct equivalents thereof.
- 5.) (original) A binding molecule comprising
- a first antigen binding site comprising in sequence the hypervariable regions CDR1-11C7 (SEQ ID NO: 8), CDR2-11C7 (SEQ ID NO: 9) and CDR3-11C7 (SEQ ID NO: 10); and
 - a second antigen binding site comprising in sequence the hypervariable regions CDR1'-11C7 (SEQ ID NO: 11), CDR2'-11C7 (SEQ ID NO: 12) and CDR3'-11C7 (SEQ ID NO: 13); or
 - direct equivalents thereof.
- 6.) (currently amended) The binding molecule according to claims 1 to 5 which comprises at least
- one immunoglobulin heavy chain or fragment thereof which comprises (i) a variable domain comprising in sequence the hypervariable regions regions CDR1-11C7 (SEQ ID NO: 8), CDR2-11C7 (SEQ ID NO: 9) and CDR3-11C7 (SEQ ID NO: 10) and (ii) the constant part or fragment thereof of a human heavy chain; and
 - one immunoglobulin light chain or fragment thereof which comprises (i) a variable domain comprising in sequence the hypervariable regions CDR1'-11C7 (SEQ ID NO: 11), CDR2'-11C7 (SEQ ID NO: 12) and CDR3'-11C7 (SEQ ID NO: 13) and (ii) the constant part or fragment thereof of a human light chain; or
 - direct equivalents thereof.
7. (original) The binding molecule according to claim 6 in which the constant part or fragment thereof of the human heavy chain is of the $\gamma 4$ type and the constant part or fragment thereof of the human light chain is of the κ type.
8. (currently amended) The binding molecule according to claims 1 to 7, which is a chimeric or humanised monoclonal antibody.
9. (original) A binding molecule comprising polypeptide sequences as shown in SEQ ID NO: 2 and SEQ ID NO: 3.
10. (currently amended) A polynucleotide comprising polynucleotides encoding a binding molecule according to any of claims 1 to 9.
11. (original) A polynucleotide comprising either
- polynucleotide sequences as shown in SEQ ID NO: 14, SEQ ID NO: 15 and SEQ ID NO: 16;
 - or

- polynucleotide sequences as shown in SEQ ID NO: 17, SEQ ID NO: 18 and SEQ ID NO: 19.
12. (currently amended) An expression vector comprising polynucleotides according to ~~any one~~ of claims 10 ~~or~~ 11.
 13. (currently amended) An expression system comprising a polynucleotide according to ~~any one of claims 10 or 11~~, wherein said expression system or part thereof is capable of producing a polypeptide of ~~any one of claims 1 to 9~~, when said expression system or part thereof is present in a compatible host cell.
 14. (original) An isolated host cell which comprises an expression system according to claim 13.
 15. (currently amended) The use of a binding molecule according to ~~any one of claims 1 to 9~~ as a pharmaceutical.
 16. (currently amended) The use of a binding molecule according to ~~any one of claims 1 to 9~~ in the treatment of nerve repair.
 17. (currently amended) A pharmaceutical composition comprising a binding molecule according to ~~any one of claims 1 to 9~~ in association with at least one pharmaceutically acceptable carrier or diluent.
 18. (currently amended) A method of treatment of diseases associated with nerve repair comprising administering to a subject in need of such treatment an effective amount of a binding molecule according to ~~any one of claims 1 to 9~~.